Success examples
Cell-free Hemoglobin-Oxidized LDL Axis Contributes to Microvascular Endothelial Barrier Dysfunction and Poor Outcomes During Sepsis

Meegan J. E., Tomasek T., Desco A., Ware L. B., Bastarache J. A.

The FASEB Journal 2022, Vol. 36, No. 1. open access.

LOX-1 inhibitor
DOI
Success examples
Designing Soluble PROTACs: Strategies and Preliminary Guidelines

Jiménez D. G., Sebastiano M. R., Vallaro M., Mileo V., Pizzirani D., Moretti E., Ermondi G., Caron G.

J Med Chem 2022, 65(19):12639-12649.

PTK2 PROTAC PTK2 PROTAC
DOI
PubMed
Success examples
BTB BCL6 dimers as building blocks for reversible drug-induced protein oligomerization

Nitsch L., Jensen P., Yoon H., Koeppel J., Burman S. S. R., Fischer E. S., Scholl C., Fröhling S., Słabicki M.

Cell Rep Methods 2022, 2(4):100193.

BCL6 degrader BCL6 inhibitor BCL6 degrader
DOI
PubMed
Success examples
Identification of Sodium Transients Through Na V 1.5 Channels as Regulators of Differentiation in Immortalized Dorsal Root Ganglia Neurons

Martínez A. L., Brea J., Domínguez E., Varela M. J., Allegue C., Cruz R., Monroy X., Merlos M., Burgueño J., Carracedo A., Loza M. I.

Front Cell Neurosci 2022, 16:816325. open access

Nav1.2 channel blocker
DOI
PubMed
Success examples
Residency time of agonists does not affect the stability of GPCR-arrestin complexes

Mösslein N., Pohle L. G., Fuss A., Bünemann M., Krasel C.

Br J Pharmacol 2022, 179(16):4107-4116. open access

β2AR agonist
DOI
PubMed
Success examples
Targeting Cathepsin C in PR3-ANCA Vasculitis

Jerke U., Eulenberg-Gustavus C., Rousselle A., Nicklin P., Kreideweiss S., Grundl M. A., Eickholz P., Nickles K., Schreiber A., Korkmaz B., Kettritz R.

J Am Soc Nephrol 2022, 33, 5, 936-947.

Cathepsin C inhibitor
DOI
PubMed